Skip to main content
SpringerLink
Log in

Evaluation of potential of miR-8073 and miR-642 as diagnostic markers in pancreatic cancer

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

Pancreatic cancer is a cancer with an insidious course. Since disease is often diagnosed at advanced stages, clinical outcome is impaired. Thus identification of biomarkers for this malignancy has importance in enhancement of patients’ survival.

Methods and results

In the current study, we assessed expression levels of miR-8073 and miR-642 in the circulation of 50 patients with pancreatic cancer and 50 controls. Plasma levels of miR-8073 and miR-642 were significantly higher in patients with pancreatic cancer compared with controls (P value < 0.0001 and P value = 0.0068, respectively). Plasma levels of miR-642 were inversely correlated with albumin levels (R=-0.28, P value = 0.049), WBC count (R=-0.35, P value = 0.01), as well as CRP level (R=-0.30, P value = 0.035). On the other hand, levels of this miRNA were positively correlated with lipase level (R = 0.29, P value = 0.042). Levels of miR-8073 were not correlated with any of the available parameters. Plasma levels of miR-8073 could separate patients with pancreatic cancer from controls with AUC, sensitivity and specificity values of 0.82, 0.77 and 0.78, respectively. miR-642 could differentiate these two groups with AUC, sensitivity and specificity values of 0.63, 0.58 and 0.78, respectively. Combination of these two parameters resulted in AUC, sensitivity and specificity values of 0.79, 0.77 and 0.78, respectively.

Conclusions

Taken together, these two miRNAs are suggested as possible blood markers for pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians 71(3) 209–249

  2. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F (2020) Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(1):335–349e15

    Article  Google Scholar 

  3. Ferlay J, Partensky C, Bray F (2016) More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol 55(9–10):1158–1160

    Article  CAS  Google Scholar 

  4. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O (2018) Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 18(1):1–11

    Article  Google Scholar 

  5. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7(4):e1000267

    Article  Google Scholar 

  6. Fathi M, Ghafouri-Fard S, Abak A, Taheri M (2021) Emerging roles of miRNAs in the development of pancreatic cancer. Biomed Pharmacother 141:111914

    Article  CAS  Google Scholar 

  7. Eid M, Karousi P, Kunovský L, Tuček Å, Brančíková D, Kala Z, Slabý O, Mayer J, Kontos CK, Trna J (2021) The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma,Biomedicines9(10)

  8. Mizoguchi A, Takayama A, Arai T, Kawauchi J, Sudo H (2018) MicroRNA-8073: Tumor suppressor and potential therapeutic treatment. PLoS ONE 13(12):e0209750–e0209750

    Article  CAS  Google Scholar 

  9. Yu Z, Du Y, Li H, Huang J, Jiang D, Fan J, Shen Y, Zhang L, Yu X, Xu N, Ke Q (2020) miR-642 serves as a tumor suppressor in hepatocellular carcinoma by regulating SEMA4C and p38 MAPK signaling pathway. Oncol Lett 20(4):74

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang X, Song Z, Hu B, Chen Z, Chen F, Cao C (2021) MicroRNA–642a–5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1. Oncol Rep 45(3):933–944

    Article  Google Scholar 

  11. Braoudaki M, Lambrou GI, Giannikou K, Milionis V, Stefanaki K, Birks DK, Prodromou N, Kolialexi A, Kattamis A, Spiliopoulou CA (2014) Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. J Hematol Oncol 7(1):1–18

    Article  Google Scholar 

  12. Quwaider D, Corchete LA, Misiewicz-Krzeminska I, Sarasquete ME, Pérez JJ, Krzeminski P, Puig N, Mateos MV, García-Sanz R, Herrero AB (2017) DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol Oncol 10(1):1–12

    Article  Google Scholar 

  13. Korc M (2014) p38 MAPK in pancreatic cancer: finding a protective needle in the haystack. Clin Cancer Res 20(23):5866–5868

    Article  CAS  Google Scholar 

  14. Shams R, Saberi S, Zali M, Sadeghi A, Ghafouri-Fard S, Aghdaei HA (2020) Identification of potential microRNA panels for pancreatic cancer diagnosis using microarray datasets and bioinformatics methods. Sci Rep 10(1):1–15

    Article  Google Scholar 

  15. Lee JM, Lee HS, Hyun JJ, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Chun HJ, Um SH, Kim CD (2016) Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol 8(7):555–562

    Article  Google Scholar 

  16. Stotz M, Barth DA, Riedl JM, Asamer E, Klocker EV, Kornprat P, Hutterer GC, Prinz F, Lackner K, Stöger H, Gerger A, Pichler M (2020) The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Cancers (Basel) 12(7):1798

    Article  CAS  Google Scholar 

  17. Xu S-S, Li S, Xu H-X, Li H, Wu C-T, Wang W-Q, Gao H-L, Jiang W, Zhang W-H, Li T-J, Ni Q-X, Liu L (2020) Yu, Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer. World J Gastroenterol 26(8):828–838

    Article  CAS  Google Scholar 

  18. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ (2013) The clinical utility of CA 19 – 9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 13(3):340–351

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The current study was supported by a grant from Shahid Beheshti University of Medical Sciences.

Funding

The current study was supported by a grant from Shahid Beheshti University of Medical Sciences.

Author information

Authors and Affiliations

  1. Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Mohadeseh Fathi & Soudeh Ghafouri-Fard

  2. Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Hamid Asadzadeh Aghdaie & Roshanak Shams

Authors
  1. Mohadeseh Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamid Asadzadeh Aghdaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soudeh Ghafouri-Fard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roshanak Shams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Soudeh Ghafouri-Fard or Roshanak Shams.

Ethics declarations

Disclosure of potential conflicts of interest

Authors declare no conflicts of interest.

Research involving human participants and/or animals.

Ethical approval

The study protocol was approved by ethical committee of Shahid Beheshti University of Medical Sciences.

All procedures performed were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent forms were signed by all study participants.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fathi, M., Aghdaie, H.A., Ghafouri-Fard, S. et al. Evaluation of potential of miR-8073 and miR-642 as diagnostic markers in pancreatic cancer. Mol Biol Rep 49, 6475–6481 (2022). https://doi.org/10.1007/s11033-022-07476-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-022-07476-0

Keywords

Search

Navigation